Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Hepatitis B Virus – Epidemiology – Epidemiology Dashboard

Login to access report north_east
Contact sales account_box

Clarivate Epidemiology’s coverage of hepatitis B virus (HBV) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the total and diagnosed prevalence of HBV for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the mature markets and Europe and 10 years for the other countries we cover.

All forecast data are available on Clarivate’s Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

Clarivate Epidemiology’s HBV forecast answers the following questions:

  • How will changes in the levels of exposure to known risk or protective factors affect the number of people living with a diagnosis of HBV?
  • In developing countries, what impact will economic growth and development have on the number of people living with a diagnosis of HBV?
  • How will improvements in survival change the number of people living with a diagnosis of HBV?
  • Of all people diagnosed with HBV, how many in each of the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of HBV over the forecast period?

In addition to the total number of cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following HBV subpopulations:

  • Total hepatitis B prevalent cases
  • Total prevalent cases by diagnosis status
  • Diagnosed prevalent cases by HBeAg status
  • Diagnosed prevalent cases by liver status
  • Diagnosed prevalent cases by treatment status

Note: Coverage may vary by country.

Table of contents

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Multiple Myeloma – Current Treatment – Treatment Sequencing – Multiple Myeloma (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
north_east
Report
Epilepsy – Unmet Need – Unmet Need – Dravet Syndrome (US/EU)
Dravet syndrome (DS) is a rare, severe, pediatric-onset genetic epileptic encephalopathy that typically emerges within the first year of life and is marked by developmental delays and multiple…
north_east
Report
Alzheimer’s Disease – Unmet Need – Unmet Need – Agitation in Alzheimer’s Disease (US/EU)
Agitation affects most Alzheimer’s disease (AD) patients and comprises a constellation of disruptive symptoms for patients and their families, which may contribute to nursing home placement…
north_east
Report
Breast Cancer – Unmet Need – Unmet Need – Metastatic HR-Positive / HER2-Negative Breast Cancer (US/EU)
The landscape of advanced HR-positive / HER2-negative breast cancer treatment is continually evolving. CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio)…
north_east
Report
Hepatitis B Virus – Geographic Focus: China – China In-Depth – Hepatitis B Virus
HBV is a major public health burden in China, with chronically infected individuals at a significantly increased risk of developing hepatic cirrhosis and hepatocellular carcinoma. Current treatment…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east